<DOC>
	<DOCNO>NCT01673217</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine give together pegylated liposomal doxorubicin hydrochloride vaccine therapy treat patient recurrent ovarian epithelial cancer , fallopian tube cancer , peritoneal cancer . Drugs use chemotherapy , decitabine pegylated liposomal doxorubicin hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . Vaccines make peptide antigen may help body build effective immune response kill tumor cell . Giving combination chemotherapy together vaccine therapy may kill tumor cell</brief_summary>
	<brief_title>Decitabine , Vaccine Therapy , Pegylated Liposomal Doxorubicin Hydrochloride Treating Patients With Recurrent Ovarian Epithelial Cancer , Fallopian Tube Cancer , Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety 5-aza-2'-deoxycytidine ( decitabine ) combination immunization NYESO-I protein mixed montanide granulocyte-macrophage colony stimulate factor ( GM-CSF ) patient schedule receive liposomal doxorubicin recurrent epithelial ovarian , fallopian tube primary peritoneal carcinoma . SECONDARY OBJECTIVES : I . To evaluate NY-ESO-l specific cellular humoral immunity determination NY-ESO-I specific antibody , CD8+ CD4+ T-cells follow immunization NY-ESO-l protein mixed montanide GM-CSF combination 5-aza-2 ' -deoxycytidine ( decitabine ) patient receive liposomal doxorubicin recurrent epithelial ovarian , fallopian tube primary peritoneal carcinoma . II . To determine impact 5-aza-2'-deoxycytidine NY-ESO-I specific expression , NY-ESO-l promoter methylation , global DNA methylation . III . To compare time progression ( ttp ) propose therapy ttp standard therapy ( historical study ) . OUTLINE : This dose escalation study decitabine . Patients receive decitabine intravenously ( IV ) 3 hour day 1 , pegylated liposomal doxorubicin hydrochloride IV day 8 , NY-ESO-1 peptide vaccine emulsify incomplete Freund 's adjuvant sargramostim subcutaneously day 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 month .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Subjects relapse epithelial ovarian cancer ( include fallopian tube primary peritoneal cancer ) receive liposomal doxorubicin salvage therapy recurrent disease Patients may receive four previous line chemotherapy The relapse may define increase CA125 ; may may either measurable symptomatic disease Any human leukocyte antigen ( HLA ) type No requirement tumor expression NYESO1 Karnofsky performance status &gt; 70 % Not previously treat doxorubicin Life expectancy &gt; = 6 month Hematology biochemistry laboratory result within limit normally expect patient population , without evidence major organ failure No immunodeficiency Have inform treatment option Able willing give valid write informed consent Neutrophil count &gt; = 1.5 x 10^9 Platelet count &gt; = 100 x 10^9 Serum creatinine = &lt; 2.1 mg/dL Serum bilirubin = &lt; 2 mg/dL Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 2.6 x upper limit normal ( ULN ) ( normal range : AST 1546 U/L ; ALT 1166 U/L ) Metastatic disease central nervous system therapeutic option , include radiotherapy , may available Other serious illness ( e.g. , serious infection require antibiotic , bleed disorder ) History autoimmune disease ( e.g. , thyroiditis , lupus ) except vitiligo Concomitant systemic treatment corticosteroid , antihistamine nonsteroidal antiinflammatory drug ; specific CQX2 inhibitor permit Chemotherapy , radiation therapy , immunotherapy within 4 week prior first dose study agent ( 6 week nitrosoureas ) Known human immunodeficiency virus ( HIV ) positivity Known allergy history life threaten reaction GMCSF Myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , chest pain shortness breath activity , heart condition treat doctor Participation clinical trial involve another investigational agent within 4 week prior first dose study agent Mental impairment may compromise ability give informed consent comply requirement study Lack availability patient immunological clinical followup assessment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>